Spectrum Pharma (SPPI) Provides Update on ROLONTIS Pre-Approval Inspection
Get Alerts SPPI Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 14.6%
EPS Growth %: +100.0%
Join SI Premium – FREE
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the pre-approval inspection at the ROLONTIS® (eflapegrastim) manufacturing site in May 2021. In October 2020, the company received notification from the agency that it would defer its decision on the BLA because an inspection of the Hanmi Bioplant in South Korea could not be conducted during the review cycle due to restrictions on travel related to the COVID-19 pandemic.
“I am thrilled that the FDA informed us that they will be conducting a pre-approval inspection of the ROLONTIS manufacturing facility in May,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We believe the pre-approval inspection marks the final step in the ROLONTIS review process.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!